Global Cancer Biomarkers Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Cancer Biomarkers Market, By Type (Genetic Biomarkers, Protein Biomarkers, Other Cancer Biomarkers) Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer and Other Cancer Types), Technology (Imaging Technologies, Omic Technologies, Cytogenetic-Based Tests and Immunoassays), Applications  (Drug Discovery and Development, Personalized Medicine, Diagnostics and Others), End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centres and Diagnostic Laboratories)– Industry Trends and Forecast to 2029.

Cancer Biomarkers Market

Market Analysis and Size

Cancer is one of the highest prevailing disease in the world. According to a report by World Health Organization (WHO), cancer is the second most leading cause of deaths globally. In many cases, cancer isn’t diagnosed up until the last stage and it is very difficult for the body to recover from that stage. This led to the introduction of biomarkers in the field of diagnostic technology. Cancer biomarkers are increasingly gaining importance in the developing economies coupled with growing awareness about them in the remote areas.                        

  • Data Bridge Market Research analyses that the cancer biomarkers market is expected to undergo a CAGR of 13.11% during the forecast period. This indicates that the market value, which was USD 11.66 billion in 2021, would rocket up to USD 51.14 billion by 2029. “Lung Cancer” dominates the product segment of the cancer biomarkers market owing to the fact that lung cancer has the highest prevalence rate in the world as compared to other cancer types. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

From the name itself, it is clear that cancer biomarkers are the biomolecules that are used for determining cancer in the body. The cancer biomarkers are effective in diagnosing the cancerous cells in a particular area or organ in the body. These biomolecules are analysed by collecting samples of stool, urine, tumour tissue, blood, and other bodily fluids.   

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units,  Pricing in USD

Segments Covered

Type (Genetic Biomarkers, Protein Biomarkers, Other Cancer Biomarkers) Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer and Other Cancer Types), Technology (Imaging Technologies, Omic Technologies, Cytogenetic-Based Tests and Immunoassays), Applications  (Drug Discovery and Development, Personalized Medicine, Diagnostics and Others), End User (Hospitals, Academic and Cancer Research Institutes, Ambulatory Surgical Centres and Diagnostic Laboratories)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Abbott. (US), DiagnoCure Inc. (Canada), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated. (US), Merck KGaA, (Germany), Hologic, Inc. (US), BD. (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Pfizer, Inc. (US), Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (US)

 

Cancer Biomarkers Market Dynamics

Drivers

  • The rise in the prevalence of cancer

Surging prevalence of cancer especially lung cancer all around the globe is one of the major factors responsible for fostering growth in the market value. According to a recent data, more than 70% of the deaths occur from cancer in low- and middle-income countries. Factually, 1 in 6 people suffer from some or the other cancer.  

  • Research and development proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies being conducted for drug discovery is also bolstering the market growth rate.

  • Government investments on healthcare infrastructure

The increase in the funding by the federal government is set to drive the market growth rate. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities.

Additionally, surge in the personal disposable income level, introduction of technologically driven product in hospitals and increasing investment for the development of advanced, governmental support in approving the novel drugs pertaining to the cancer biomarkers, positively affect the market growth rate.

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, increasing popularity of personalized medicine, increasing awareness regarding malignancies among patients and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, surging number of strategic collaborations, rising internet penetration rate, growing number of hospitals and laboratories, higher acceptance of treatments for cancer in the developing regions and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities and lack of clarity regarding several basic elements including the utility of biomarker-based tests are expected to obstruct market growth. Also, lack of favourable reimbursement scenario and technology penetration in the developing economies, technical issues related to sample collection and storage, existing threat of failure of cancer treatment and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This cancer biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Cancer Biomarkers Market

COVID-19 has significantly and negatively impacted the market. The funding for research and development activities was significantly reduced and cut down. Supply chain disruptions demoted the market demand and supply. Shifting focus towards the essential healthcare procedures during this phase put a halt on unnecessary operations. There was a huge postponement on the non-essential medical procedures. All of this proved to be a bane for the market during pandemic.

Recent Development

  • In March 2021, Roche received approval from US FDA for VENTANA ALK (D5F3) CDx Assay.
  • In July 2020, Thermo Fisher Scientific signed a companion diagnostic (CDx) agreement with Vhugai Pharmaceutical Co., Ltd to increase the use of Oncomine Dx Target Test in Japan.   

Global Cancer Biomarkers Market Scope

The cancer biomarkers market is segmented on the basis of type, cancer type, technology, applications and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Genetic Biomarkers
  • Protein Biomarkers
  • Other Cancer Biomarkers

On the basis of type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers and other cancer biomarkers.

Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Melanoma
  • Ovarian Cancer
  • Liver Cancer
  • Stomach Cancer
  • Other Cancer Types

On the basis of cancer type, the cancer biomarkers market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer and other cancer types. 

Technology

  • Imaging Technologies
  • Omic Technologies
  • Cytogenetic-Based Tests
  • Immunoassays

On the basis of technology, the cancer biomarkers market is segmented into imaging technologies, omic technologies, cytogenetic-based tests and immunoassays.

Applications

  • Drug Discovery and Development
  • Personalized Medicine
  • Diagnostics
  • Others

On the basis of application, the cancer biomarkers market is segmented into drug discovery and development, personalized medicine, diagnostics and others.

End user

  • Hospitals
  • Academic and Cancer Research Institutes
  • Ambulatory Surgical Centres
  • Diagnostic Laboratories

The global cancer biomarkers market is also segmented on the basis of end users into hospitals, academic and research institutions, ambulatory surgical centres and diagnostic laboratories.

Cancer Biomarkers Market Regional Analysis/Insights

The cancer biomarkers market is analysed and market size insights and trends are provided by country, type, cancer type, technology, applications and end user as referenced above.

The countries covered in the cancer biomarkers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer biomarkers market because of the strong base of healthcare facilities, rising investment from key players in the growth of the advanced devices, growing number of processes pertaining to drug development, detection of specific tumours, monitoring biological response to cancer therapy and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, rising prevalence of cancer and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The cancer biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer biomarkers market. The data is available for historic period 2010-2020.

Competitive Landscape and Cancer Biomarkers Market Share Analysis

The cancer biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer biomarkers market.

Some of the major players operating in the cancer biomarkers market are Abbott. (US), DiagnoCure Inc. (Canada), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated. (US), Merck KGaA, (Germany), Hologic, Inc. (US), BD. (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Pfizer, Inc. (US), Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (US) among others.

Research Methodology : Global Cancer Biomarkers Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available : Global Cancer Biomarkers Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Cancer Biomarkers Market will be projected USD 51.14 billion during the forecast period of 2022 to 2029.
The Cancer Biomarkers Market is Projected to Grow at a CAGR of 13.11% During the Forecast Period of 2022 to 2029
Factors such as the increasing acceptance of minimally invasive and non-invasive aesthetic processes, the growing acceptance of the aesthetic treatments amongst the elderly individuals and increasing personal disposable income are the major growth driving factors for Cancer Biomarkers Market.
Abbott. (US), DiagnoCure Inc. (Canada), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (US) are the major companies operating in Cancer Biomarkers region.
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.